Rosetta Genomics Ltd. is a molecular diagnostics company with offices in Israel and the United States that uses micro-ribonucleic acid biomarkers to develop diagnostic tests designed to differentiate between various types of cancer. The company expects the first three tests based on its technology to be submitted for regulatory approval in 2008.

PropertyValue
dbpedia-owl:Company/industry
dbpedia-owl:Company/product
dbpedia-owl:Organisation/foundationDate
  • 2000-01-01 00:00:00 (xsd:date)
dbpedia-owl:Organisation/keyPerson
dbpedia-owl:Organisation/keyPersonPosition
  • Amir Avniel (President and CEO)
  • Dr. Isaac Bentwich (Founder)
dbpedia-owl:Organisation/locationCity
dbpedia-owl:Organisation/numberOfEmployees
  • 70 (xsd:integer)
dbpedia-owl:Organisation/type
dbpedia-owl:foundationDate
  • 2000-01-01 00:00:00 (xsd:date)
dbpedia-owl:industry
dbpedia-owl:keyPerson
dbpedia-owl:keyPersonPosition
  • Amir Avniel (President and CEO)
  • Dr. Isaac Bentwich (Founder)
dbpedia-owl:locationCity
dbpedia-owl:numberOfEmployees
  • 70 (xsd:integer)
dbpedia-owl:product
dbpedia-owl:type
dbpprop:abstract
  • Rosetta Genomics Ltd. is a molecular diagnostics company with offices in Israel and the United States that uses micro-ribonucleic acid biomarkers to develop diagnostic tests designed to differentiate between various types of cancer. The company expects the first three tests based on its technology to be submitted for regulatory approval in 2008. The diagnostic tests will differentiate between squamous and non-squamous non-small cell lung cancer (NSCLC); differentiate between adenocarcinoma and mesothelioma; and seek to identify the origin of tumors in patients representing cancer of unknown primary (CUP). Using a single microRNA, the highly sensitive, highly specific test for squamous and non-squamous lung cancer has passed the prevalidation phase and has been submitted for approval to the New York State Department of Health Clinical Laboratory Evaluation Program in April 2008. In April 2008, Nature Biotechnology published a study by Rosetta Genomics’ scientists whose findings demonstrate microRNAs' significant potential to act as effective biomarkers that may be applied in a diagnostic test designed to identify the primary tumor site in patients CUP. In addition to its diagnostic programs, Rosetta Genomics is collaborating with Isis Pharmaceuticals to develop a microRNA-based therapy for Hepatocellular carcinoma (HCC), a form of liver cancer.
dbpprop:foundation
  • 2000 (xsd:integer)
dbpprop:founder
  • Dr. Isaac Bentwich
dbpprop:homepage
dbpprop:industry
dbpprop:keyPeople
dbpprop:locationCity
dbpprop:name
  • Rosetta Genomics
dbpprop:numEmployees
  • 70 (as of 2008)
dbpprop:products
dbpprop:reference
dbpprop:type
dbpprop:wikiPageUsesTemplate
dbpprop:wordnet_type
rdf:type
rdfs:comment
  • Rosetta Genomics Ltd. is a molecular diagnostics company with offices in Israel and the United States that uses micro-ribonucleic acid biomarkers to develop diagnostic tests designed to differentiate between various types of cancer. The company expects the first three tests based on its technology to be submitted for regulatory approval in 2008.
rdfs:label
  • Rosetta Genomics
owl:sameAs
foaf:homepage
foaf:name
  • Rosetta Genomics
foaf:page
is dbpprop:disambiguates of